Understanding Modality-Specific Development Challenges

Vaccines have different developmental challenges than cancer therapeutics, which can have different challenges than gene therapies. In this segment from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration,” our panelists share some of the common friction points across their respective modalities as it relates to process development. For vaccines, says Sanofi’s Eric Doerr, it’s the inefficiencies of using dated techniques or legacy technologies. For ADCs and mAbs, says Immunome’s Doug MacDonald, it can be downstream technology struggling to keep up with upstream advances. In gene therapies, says Umoja Biopharma’s Branden Salinas, Ph.D., viral vector stability and half-life can necessitate continuous or multiple harvest strategies, potentially shifting where the boundary between upstream and downstream responsibilities lies.